Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice

Journal of Immunology

Volumn 164, Issue 7, 2000, Pages 3535-3542

  Touloukian, Christopher E ^a   Leitner, Wolfgang W ^a   Topalian, Suzanne L ^a   Li, Yong F ^a   Robbins, Paul F ^a   Rosenberg, Steven A ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 100; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0034176020     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.7.3535     Document Type: Article

References (60)

1. Boon, T., P. G. Coulie, and B. Van den Eynde. 1997. Tumor antigens recognized by T cells. Immunol. Today 18:267.
2. Restifo, N. P., and S. A. Rosenberg. 1999. Developing recombinant and synthetic vaccines for the treatment of melanoma. Curr. Opin. Oncol 11:50.
3. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwartz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.
4. Marchand, M., N. van Baren, P. Weynams, V. Brichard, B. Dreno, M. H. Tessier, E. Rankin, G. Parmiani, F. Arienti, Y. Humblet, et al. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80:219.
5. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328.
6. + T cell responses in antitumor immunity. Curr. Opin. Immunol. 10:588.
7. Parry, S. L., F. C. Hall, J. Olson, T. Kamradt, and G. Sonderstrup. 1998. Autoreactivity versus autoaggression: a different perspective on human autoantigens. Curr. Opin. Immunol. 10:663.
8. Mata, M., and Y. Paterson. 1999. Th1 T cell responses to HIV-1 Gag protein delivered by a Listeria monocytogenes vaccine are similar to those induced by endogenous listerial antigens. J. Immunol. 163:1449.
9. Zajac, A. J., J. N. Blattman, K. Murali-Krishna, D. J. Sourdive, M. Suresh, J. D. Altman, and R. Ahmed. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188:2205.
10. + tumor-infiltrating lymphocytes in human solid tumors. Immunol. Res. 14:119.
11. + cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles. Int. J. Cancer 57:56.
12. Sahin, U., O. Tureci, and M. Pfreundschuh. 1997. Serological identification of human tumor antigens. Curr. Opin. Immunol. 9:709.
13. + T cell reactivity to an immunogenic model tumor antigen. J Immunol, 164:562.
14. Ossendorp, F., E. Mengede, M. Camps, R. Filius, and C. J. Melief. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187:693.
15. + cytotoxic T-cell responses during chronic viral infection. J. Virol. 68:8056.
16. von Herrath, M. G., M. Yokoyama, J. Dockter, M. B. Oldstone, and J. L. Whitton. 1996. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J. Virol. 70:1072.
17. + T cells. J. Exp. Med. 184:863.
18. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478.
19. + T cell help. J. Exp. Med 186:65.
20. + T- helper and a T-killer cell. Nature 393:474.
21. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480.
22. + T cells. J. Exp. Med. 189:757.
23. Wang, R. F., X. Wang, A. C. Atwood, S. L. Topalian, and S. A. Rosenberg. 1999. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 284:1351.
24. + T lymphocytes. J. Exp. Med. 189:767.
25. + cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J. Exp. Med. 189:871.
26. + T cells recognize nonrnutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med. 183: 1965.
27. - T cells. J. Exp. Med. 189: 1659.
28. Cormier, J. N., Y. M. Hijazi, A. Abati, P. Fetsch, M. Bettinotti, S. M. Steinberg, S. A. Rosenberg, and F. M. Marincola. 1998. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int. J. Cancer 75:517.
29. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, K. Sakaguchi, E. Appella, J. R. Yannelli, G. J. Adema, T. Miki, and S. A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91:6458.
30. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961.
31. Parkhurst, M. R., M. L. Salgaller, S. Southwood, P. F. Robbins, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157:2539.
32. Marincola, F. M., P. Shamamian, L. Rivoltini, M. Salgaller, J. Cormier, N. P. Restifo, T. B. Simonis, D. Venzon, D. E. White, and D. R. Parkinson. 1995. HLA associations in the antitumor response against malignant melanoma. J. Immunother. Emphasis. Tumor Immunol. 18:242.
33. Ito, K., H. J. Bian, M. Molina, J. Han, J. Magram, E. Saar, C. Belunis, D. R. Bolin, R. Arceo, R. Campbell, et al. 1996. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J. Exp. Med. 183:2635.
34. Wakeland, E., L. Morel, K. Achey, M. Yui, and J. Longmate. 1997. Speed congenics: a classic technique in the fast lane (relatively speaking). Immunol. Today 18:472.
35. + T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int. J. Cancer 58:69.
36. Southwood, S., J. Sidney, A. Kondo, M. F. del Guercio, E. Appella, S. Hoffman, R. T. Kubo, R. W. Chesnut, H. M. Grey, and A. Sette. 1998. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160:3363.
37. + T cell lines reactive with a self-K- ras-derived peptide in vitro, using a mAb to CD29. Hum. Immunol. 59:343.
38. Overwijk, W. W., A. Tsung, K. R. Irvine, M. R. Parkhurst, T. J. Goletz, K. Tsung, M. W. Carroll, C. Liu, B. Moss, S. A. Rosenberg, and N. P. Restifo. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188:277.
39. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA 91:9461.
40. Congia, M., S. Patel, A. P. Cope, S. De Virgiliis, and G. Sonderstrup. 1998. T cell epitopes of insulin defined in HLA-DR4 transgenic mice are derived from preproinsulin and proinsulin. Proc. Natl. Acad. Sci. USA 95:3833.
41. Gross, D. M., T. Forsthuber, M. Tary-Lehmann, C. Etling, K. Ito, Z. A. Nagy, J. A. Field, A. C. Steere, and B. T. Huber. 1998. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 281:703.
42. Halder, T., G. Pawelec, A. F. Kirkin, J. Zeuthen, H. E. Meyer, L. Kun, and H. Kalbacher. 1997. Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res. 57:3238.
43. Li, K., M. Adibzadeh, T. Halder, H. Kalbacher, S. Heinzel, C. Muller, J. Zeuthen, and G. Pawelec. 1998. Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. Cancer Immunol. Immunother. 47:32.
44. Dessen, A., C. M. Lawrence, S. Cupo, D. M. Zaller, and D. C. Wiley. 1997. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 7:473.
45. Hammer, J., E. Bono, F. Gallazzi, C. Belunis, Z. Nagy, and F. Sinigaglia. 1994. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J. Exp. Med. 180:2353.
46. Hammer, J., C. Belunis, D. Bolin, J. Papadopoulos, R. Walsky, J. Higelin, W. Danho, F. Sinigaglia, and Z. A. Nagy. 1994. High-affinity binding of short peptides to major histocompatibility complex class II molecules by anchor combinations. Proc. Natl. Acad. Sci. USA 91:4456.
47. Hammer, J., P. Valsasnini, K. Tolba, D. Bolin, J. Higelin, B. Takacs, and F. Sinigaglia. 1993. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 74:197.
48. Sonderstrup, G., and H. McDevitt. 1998. Identification of autoantigen epitopes in MHC class II transgenic mice. Immunol. Rev. 164:129.
49. Andersson, E. C., B. E. Hansen, H. Jacobsen, L. S. Madsen, C. B. Andersen, J. Engberg, J. B. Rothbard, G. S. McDevitt, V. Malmstrom, R. Holmdahl, et al. 1998. Definition of MHC and T cell receptor contacts in the HLA-DR4-restricted immunodominant epitope in type II collagen and characterization of collagen-induced arthritis in HLA-DR4 and human CD4 transgenic mice. Proc. Natl. Acad. Sci. USA 95:7574.
50. Rosloniec, E. F., D. D. Brand, L. K. Myers, Y. Esaki, K. B. Whittington, D. M. Zaller, A. Woods, J. M. Stuart, and A. H. Kang. 1998. Induction of autoimmune arthritis in HLA-DR4 (DRB1*0401) transgenic mice by immunization with human and bovine type II collagen. J. Immunol. 160:2573.
51. Theobald, M., J. Biggs, J. Hernandez, J. Lustgarten, C. Labadie, and L. A. Sherman. 1997. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med. 185:833.
52. Theobald, M., J. Biggs, D. Dittmer, A. S. Levine, and L. A. Sherman. 1995. Targeting p53 as a general tumor antigen. Proc. Natl Acad. Sci. USA 92:11993.
53. Pan, S., T. Trejo, J. Hansen, M. Smart, and C. S. David. 1998. HLA-DR4 (DRB1*0401) transgenic mice expressing an altered CD4-binding site: specificity and magnitude of DR4-restricted T cell response. J. Immunol. 161:2925.
54. Vonderheide, R. H., W. C. Hahn, J. L. Schultze, and L. M. Nadler. 1999. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10:673.
55. Parkhurst, M. R., E. B. Fitzgerald, S. Southwood, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1998. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 58:4895.
56. Rudensky, A. Y., P. Preston-Hurlburt, S. C. Hong, A. Barlow, and C. A. Janeway, Jr. 1991. Sequence analysis of peptides bound to MHC class II molecules. Nature 353:622.
57. Chicz, R. M., R. G. Urban, W. S. Lane, J. C. Gorga, L. J. Stern, D. A. Vignali, and J. L. Strominger. 1992. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 358:764.
58. Zlotnik, A., J. Morales, and J. A. Hedrick. 1999. Recent advances in chemokines and chemokine receptors. Crit. Rev. Immunol. 19:1.
59. Dieu, M. C., B. Vanbervliet, A. Vicari, J. M. Bridon, E. Oldham, S. Ait-Yahia, F. Briere, A. Zlotnik, S. Lebecque, and C. Caux. 1998. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med. 188:373.
60. Rollins, B. J. 1997. Chemokines. Blood 90:909.